Neurocrine Biosciences
NBIX
#1690
Rank
S$16.34 B
Marketcap
S$162.87
Share price
-1.13%
Change (1 day)
1.04%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): S$5.61

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is S$5.46. In 2024 the company made an earnings per share (EPS) of S$4.28 an increase over its 2023 EPS that were of S$3.22.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)S$5.6131.2%
2024S$4.2833.07%
2023S$3.2257.76%
2022S$2.0469.47%
2021S$1.20-78.21%
2020S$5.52990%
2019S$0.5181.82%
2018S$0.28-113.5%
2017S-$2.060.62%
2016S-$2.0557.28%
2015S-$1.3025.61%
2014S-$1.0418.84%
2013S-$0.87-1085.71%
2012S$0.08863

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
S$1.72-68.45%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
S$3.03-44.51%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
S$29.15 434.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
S$0.03799-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
S-$2.57-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
S$2.17-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
S-$37.86-793.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
S$2.24-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK